Trial Condition(s):
Lymphoma, Non-Hodgkin
Evaluation of Bay 59-8862 in Patients with Aggressive, Refractory Non-Hodgkin's Lymphoma
Bayer Identifier:
100389
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Trial Purpose
Almost two-thirds of lymphoma cases are Non-Hodgkin's Lymphomas (NHL). NHL is a malignant process that affects lymphoid cells found both in the lymph nodes and extranodally. Incidence and mortality rates from NHL are highest in developed countries. While many patients with aggressive NHL are curable with initial anthracycline-containing regimens, the majority of patients will relapse or prove refractory to initial therapy. The prognosis of patients with disease recurrence following a multidrug regimen is also limited. The current protocol is designed to test the safety and efficacy of BAY 59-8862 in patients with Aggressive Refractory Non-Hodgkin's Lymphoma.
Inclusion Criteria
- Measurable disease as defined by the presence of at least one measurable lesion - Failed at least one prior therapy or has achieved remission but has progressed or relapsed within 6 months of therapy - Life expectancy of at least 12 weeks - Adequate bone marrow, liver and kidney function
Exclusion Criteria
- Excluded medical conditions like: pre-existing neuropathy, active heart diseases or ischemia, serious infections, HIV infection, chronic hepatitis B or C, seizures, hypersensitivity to taxanes, organ transplants, some previous cancers - Excluded therapies and medications, previous and concomitant such as: anticancer chemotherapy or immunotherapy during the study or within 4 weeks prior to study entry; more than two prior anticancer chemotherapy regimens; radiotherapy during study or within 4 weeks prior to study entry; bone marrow transplant - Others: pregnant or breast-feeding patients; both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial; substance abuse, medical, psychological or social conditions that may interfere with the patient's participation
Trial Summary
Enrollment Goal
Trial Dates
Phase
Could I receive a placebo?
Products
Accepts Healthy Volunteers
Where to Participate
| Locations | Status | |
|---|---|---|
Locations Centre Hospitalier Universitaire Brabois - Vandoeuvre-les-Na VANDOEUVRE-LES-NANCY, France, 54500 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Centre Hospitalier Lyon Sud - Pierre Bénite PIERRE BENITE, France, 69495 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations LSU Health Sciences Center Shreveport, United States, 71130-4228 | Status Terminated | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Rotterdam Cancer Institute Groene Hilledijk, Netherlands | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Kliniken und Polikliniken der Albert-Ludwigs-Universität Freiburg, Germany, 79106 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Kent Oncology Centre Maidstone, United Kingdom, ME16 9QQ | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations North Shore University Hospital Manhasset, United States, 11030-3876 | Status Terminated | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations New York Medical College Valhalla, United States, 10595 | Status Terminated | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Mt. Sinai Comprehensive Cancer Center Miami Beach, United States, 33140 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Medical College of Wisconsin Milwaukee, United States, 53226 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations West Clinic Memphis, United States, 38120 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Cleveland Clinic Cleveland, United States, 44195 | Status Terminated | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations University of Washington Medical Center Seattle, United States, 98195 | Status Terminated | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations University of Chicago Chicago, United States, 60637 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Cross Cancer Institute Edmonton, Canada, T6G 1Z2 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Vrije Universiteit Medisch Centrum AMSTERDAM, Netherlands, 1081 HV | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Montefiore Medical Center Bronx, United States, 10467-2490 | Status Terminated | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Addenbrookes Hospital Cambridge, United Kingdom, CB2 0QQ | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Charité Campus Benjamin Franklin Berlin, Germany, 12200 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Hôtel Dieu - Paris PARIS, France, 75151 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations HemOnCare, PC Brooklyn, United States, 11235-3518 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations The Cancer Institute of New Jersey New Brunswick, United States, 08903-2681 | Status Terminated | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Upstate Medical University Syracuse, United States, 13210-2399 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
For details, please refer to trial results
Additional Information
Copyright © Bayer
Powered by
